Angel Medical Systems is an innovator in today’s cardiac medical device arena. The company has developed the AngelMed Guardian system, which is designed to detect and warn patients of acute episodes of cardiac ischemia related to the progression of coronary artery disease and thrombotic coronary occlusion caused by vulnerable plaque ruptures.
Having completed both US and OUS clinical trials, the company has recently enrolled over 900 patients for its ALERTS Phase II US Pivotal Study. Commercially available in Brazil, this leading-edge cardiac device has been developed to reduce time to treatment, minimize heart muscle damage, and improve patient outcomes. In 2010, AngelMed received CE market approval for the commercial sale of the AngelMed Guardian System in Europe.
For its groundbreaking work, AngelMed has received several honors.